Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW versus Nimenrix or NeisVac-C in healthy toddlers
2018-003790-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Meningococcal conjugate vaccine quadrivalent, Meningococcal polysaccharide vaccine group W-135 and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (3 arms), sponsored by Sanofi. Primary endpoint: Seroprotection against meningococcal serogroup C by hSBA. Started Apr 2019; status: completed.
02
Drugs
Meningococcal conjugate vaccine quadrivalentMeningococcal polysaccharide vaccine group W-135Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2018-003790-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003790-10.